Cover Image
Market Research Report

Dengue Testing Market - Growth, Trends, and Forecasts (2020 - 2025)

Published by Mordor Intelligence LLP Product code 921264
Published Content info 110 Pages
Delivery time: 2-3 business days
Price
Back to Top
Dengue Testing Market - Growth, Trends, and Forecasts (2020 - 2025)
Published: June 1, 2020 Content info: 110 Pages
Description

The dengue testing market will show rapid growth due to the increasing incidences of dengue cases and increasing awareness campaigns to educate about the ills of dengue.

The overall incidence of dengue, as well as the explosive outbreaks of dengue, has been increasing dramatically over the last several years. According to the World Health Organization, the number of cases reported has increased from 2.2 million in 2010 to over 3.34 million in 2016. ), each year an estimated 390 million dengue infections occur around the world. Of these, around 500,000 cases develop into dengue hemorrhagic fever or severe dengue, a more severe form of the disease, which results in up to 25,000 deaths annually, across the world.

Although the full global burden of the disease is uncertain, the initiation of activities to record all dengue cases partly explains the sharp increase in the number of cases reported in recent years. Therefore not only the number of cases is increasing as the disease spreads to new areas, but explosive outbreaks are occurring. Among travelers returning from low- and middle-income countries, dengue is the second most diagnosed cause of fever after malaria. Therefore the rising prevalence of dengue virus has raised the demand for more number of diagnostic kits, which is expected to drive the dengue testing market in the near future.

Key Market Trends

ELISA-Based Tests is Expected to Dominate the Product Type Segment During the Forecast Period

The most widely used method for diagnosing dengue is an enzyme-linked immunosorbent assay (ELISA) which measures anti-DENV IgM or IgG antibodies in patient serum. The early diagnosis and management of dengue help to reduce the morbidity and mortality rates of severe forms of dengue disease as well as decrease the risk of wider outbreaks.

The enzyme-linked immunosorbent assay (ELISA) is capable of detecting NS1 antigens and differentiating among the four dengue virus serotypes. ELISA kits are found to have superior sensitivity when compared to RDTs. Because of their superior performance, ELISAs would be the recommended diagnostic choice when laboratories with trained personnel and equipment are available.

Moreover, RT-PCR tests also anticipated having a notable growth rate owing to new product launches, advancements in technologies, and accuracy. For instance, in April 2019, Beroni Group Limited signed an exclusive license agreement with Columbia University whereby Columbia University grants to Beroni and its affiliates to distribute the patented CII-ArboViroPlex rRT-PCR assay on a worldwide basis. The CII-ArboViroPlex rRT-PCR assay is an effective means to detect four viruses - Zika (ZIKV), Dengue (DENV), Chikungunya (CHIKV), and West Nile (WNV).

Asia Pacific is Found Leading the Dengue Testing Market

Asia pacific is found to be leading in the global dengue testing market as there are millions of cases of dengue infection every year. In India, there has been more than 300 per cent hike in the dengue cases since 2009 and even the total number of deaths in 2017 was the highest in the last one decade. Dengue fever is most common in Southeast Asia and the disease has been increasing rapidly. There are also several research organisations that have shown interest in developing new lines of medication for treating dengue.

The market for dengue testing in the Asia Pacific is thus expanding at a fast pace on account of the rising incidence of infectious diseases, including dengue, in India, Pakistan, and Sri Lanka.

Moreover, According to the World Health Organization, the highest number of dengue cases were recorded in 2019, All regions were affected, and dengue transmission was recorded in Afghanistan for the first time. The American region alone reported 3.1 million cases, with more than 25,000 classified as severe. Despite this alarming number of cases, deaths associated with dengue were fewer than in the previous year.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to market growth. Recently the Telenor Heath's Tonic has launched "Home Diagnostic Tests" service for dengue with video consultation through their "Tonic App". The major companies that are functioning in the global dengue testing market include Abbott Laboratories, NovaTec Immundiagnostica GmbH, Euroimmun AG (PerkinElmer), F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and InBios International, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Table of Contents
Product Code: 67161

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase Incidences of Dengue Cases
    • 4.2.2 Increasing Awareness Campaigns to Educate About the Ills of Dengue
  • 4.3 Market Restraints
    • 4.3.1 Unavailability of Effective Diagnostic Tools
    • 4.3.2 High Price of Existing Test Kits
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 ELISA-based Tests
    • 5.1.2 RT-PCR based Tests
    • 5.1.3 Dengue IgG/IgM Rapid Test
    • 5.1.4 Other Tests
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific Inc.
    • 6.1.2 F. Hoffmann-La Roche Ltd.
    • 6.1.3 Abbott Laboratories
    • 6.1.4 InBios International, Inc.
    • 6.1.5 NovaTec Immundiagnostica GmbH
    • 6.1.6 Euroimmun AG (Sub. PerkinElmer)
    • 6.1.7 Certest Biotec S.L.
    • 6.1.8 OriGene Technologies
    • 6.1.9 Abnova Corporation
    • 6.1.10 Diasorin​ (American Standard Companies)

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top